Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 6/20 | 0.53 |
| ▸ | CRACR2A | Q9BSW2 | 8/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.52 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529365 | 0.95 | IL2 (0.52) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL15529453 | 0.94 | IL2 (0.55) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL15529826 | 0.89 | IL2 (0.57) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL30096532 | 0.88 | IL2 (0.53) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL15529867 | 0.88 | IL2 (0.53) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL17318709 | 0.88 | EPHX2 (0.65) | CRACR2AEPHX2 | |
| SCHEMBL15529650 | 0.85 | CRACR2A (0.69) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL30096555 | 0.85 | CRACR2A (0.69) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL15528875 | 0.85 | CRACR2A (0.61) | IL2CRACR2ATNFSTIM1ORAI1 | |
| SCHEMBL15529478 | 0.85 | CRACR2A (0.52) | IL2CRACR2ATNFSTIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | claimed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2844656-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | claimed |
| WO-2013164773-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9409898-B2 | Substituted pyrazole compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| EP-2844656-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013164773-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111925-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | IL2 2916/4885CRACR2A 127/4885TNF 3547/4885 |
| US-20160304507-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | IL2 2916/4885CRACR2A 127/4885TNF 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.